10-QPeriod: Q1 FY2020

IDEXX LABORATORIES INC /DE Quarterly Report for Q1 Ended Mar 31, 2020

Filed April 30, 2020For Securities:IDXX

Summary

IDEXX Laboratories Inc. reported solid revenue growth of 8.7% to $626.3 million for the first quarter of 2020, compared to the same period in 2019. This growth was primarily driven by strong performance in the Companion Animal Group (CAG) segment, particularly in recurring revenue streams like consumables and reference laboratory services, which saw 10.0% organic growth. Despite the emerging impact of the COVID-19 pandemic starting in mid-March, which began to affect instrument placements and reference laboratory volumes, the company's diversified business segments, including Water and Livestock, Poultry & Dairy (LPD), also showed robust revenue increases. The company also took proactive steps to manage costs and enhance liquidity in response to the pandemic, including salary reductions and suspending share repurchases, and further strengthened its financial position with additional debt financing in April 2020. While the company experienced some negative impacts from COVID-19 late in the quarter, particularly affecting elective veterinary procedures and thus CAG instrument sales, overall financial performance remained resilient. The company's strong recurring revenue model, coupled with disciplined cost management and a strengthened liquidity position, positions it to navigate the ongoing uncertainties. Investors should note the company's forward-looking statements highlighting the continued evolution of COVID-19's impact and the company's proactive measures to maintain operations and financial flexibility.

Financial Highlights

52 data points
Beta

Revenue

$626.34M

57.4% Gross Margin

Net Income

$111.86M

17.9% Net Margin

EPS (Diluted)

$1.29

Total Assets

$1.89B

Cash & Equivalents

$81.39M

Free Cash Flow

-$21.13M

Financial Statements
Beta
Revenue$626.34M
Cost of Revenue$266.75M
Gross Profit$359.59M
R&D Expenses$33.31M
Operating Income$144.32M
Interest Expense$7.69M
Net Income$111.86M
EPS (Basic)$1.31
EPS (Diluted)$1.29
Shares Outstanding (Basic)85.43M
Shares Outstanding (Diluted)86.70M

Key Highlights

  • 1Total revenue increased by 8.7% to $626.3 million, driven by strong performance across segments, particularly CAG.
  • 2Companion Animal Group (CAG) segment revenue grew 8.5% to $551.0 million, with CAG Diagnostics recurring revenue up 10.0% organically.
  • 3The company proactively managed costs in response to COVID-19, including temporary salary reductions and suspending share repurchases.
  • 4Liquidity was enhanced in April 2020 with a $200 million senior notes issuance and an expanded $1 billion Credit Facility.
  • 5Net income attributable to IDEXX stockholders increased by 8.9% to $111.8 million, resulting in diluted EPS of $1.29, up from $1.17 in the prior year.
  • 6The company continues to monitor and adapt to the evolving impacts of the COVID-19 pandemic, which began to affect business in mid-March.
  • 7Gross profit margin saw a slight decrease of 20 basis points to 57.4% due to the initial impacts of COVID-19 and incremental investments, partially offset by strong sales volumes and pricing.

Frequently Asked Questions

The COVID-19 pandemic began to impact IDEXX's results in mid-March 2020. The primary effects were seen in the Companion Animal Group (CAG) segment, leading to a decrease in companion animal clinical visits, delays in elective procedures, and a consequent reduction in demand for CAG instruments and a slowdown in reference laboratory volumes. However, the Water and Livestock, Poultry & Dairy (LPD) segments experienced accelerated stocking orders due to the pandemic. The company implemented cost-saving measures and enhanced liquidity to mitigate these impacts.

IDEXX maintained a strong financial position. As of March 31, 2020, the company had $81.4 million in cash and cash equivalents. In April 2020, IDEXX further strengthened its financial flexibility by issuing $200 million in senior notes and expanding its Credit Facility to $1 billion. The company believes these resources, along with operational cash flow, will be sufficient to fund its operations and growth initiatives for the next twelve months and beyond.

Total revenue grew by 8.7% to $626.3 million. The Companion Animal Group (CAG) segment, the largest contributor, grew by 8.5% to $551.0 million, driven by recurring revenue streams. The Water segment saw a 12.7% increase to $34.1 million, and the Livestock, Poultry & Dairy (LPD) segment increased by 8.4% to $34.2 million. These growths were largely organic, with some benefits from accelerated stocking orders in the Water and LPD segments due to COVID-19.

In response to the emerging economic uncertainties from COVID-19, IDEXX implemented proactive cost management measures. These included temporary reductions in salaries for executives and most salaried employees, suspension of cash compensation for the Board of Directors, and other cost-saving initiatives aimed at reducing quarterly operating expenses by approximately $25 million compared to the original plan. Share repurchase activity was also suspended.